Abbott Laboratories' $(ABT)$ stock fell 0.8% in premarket trading after first-quarter sales missed Wall Street's expectations, despite better-than-expected adjusted earnings. The healthcare products company also reaffirmed its full year outlook.
The Abbott Park, Ill.-based company's adjusted first-quarter profit of $1.09 a share beat the FactSet consensus estimate of $1.07 a share.
Sales rose 4% year-over-year to $10.358 billion. Analysts surveyed by FactSet were looking for sales of $10.406 billion.
The company also reaffirmed its previously-provided full-year financial guidance. Abbott Labs expects full-year 2025 organic sales growth in the range of 7.5% to 8.5% and full-year adjusted earnings of $5.05 to $5.25 a share.
For the second quarter, Abbott Labs expects adjusted earnings of $1.23 to $1.27 a share. Analysts surveyed by FactSet are looking for second-quarter earnings of $1.25 a share.
(This is a developing news story with updates to come.)
-James Rogers
For more from MarketWatch: http://www.marketwatch.com/newsviewer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 16, 2025 07:58 ET (11:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。